Azora Therapeutics, Inc. (DE)

AZR Nasdaq SEC CIK 1513525
Follow Azora Therapeutics, Inc. (DE) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$64.6M −3498.8% vs same quarter last year
EPS, diluted −$4.52 −123.8% vs same quarter last year
Operating cash flow −$6.6M −261.9% vs same quarter last year
Operating income −$7.5M −326.9% vs same quarter last year
Net income by quarter
−$13.2T
−$2.2M
−$2M
−$1.8M
−$7.98T
−$2M
−$52M
−$64.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
−$15T−$10T−$5T$0FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$7.98T
FY24−$13.2T
FY23−$5.12T
FY22−$12.7M
FY21−$19.4M
FY20−$10.9M
FY19−$8.6M
FY18−$11.6M
FY17−$1.1M
FY16-